daratumumab,Elotuzumab,carfilzomib,dexamethasone,Lenalidomide
janssen,AbbVie,BMS
['dara ', 'mmsm']
critiques:
- too early to conclude anything about this study - low number of high risk myeloma patients enrolled - if pfs is better in elo-krd! how will oncologists choose this induction therapy over dara based #mmsm #myeloma #usmirc #asco23 #medtwitter
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter